|本期目录/Table of Contents|

[1]魏萌,姜哲轶,陆逸华,等.端粒酶抑制剂BIBR1532通过影响NF-κB信号通路调控血小板活化[J].国际心血管病杂志,2025,01:47-51.
　WEI Meng,JIANG Zheyi,LU Yihua,et al.Telomerase inhibitor BIBR1532 regulates platelet activation via NF-κB signaling pathway[J].International Journal of Cardiovascular Disease,2025,01:47-51.
点击复制

端粒酶抑制剂BIBR1532通过影响NF-κB信号通路调控血小板活化(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2025年01期
页码:
47-51
栏目:
基础研究
出版日期:
2025-01-25

文章信息/Info

Title:
Telomerase inhibitor BIBR1532 regulates platelet activation via NF-κB signaling pathway
作者:
魏萌; 姜哲轶; 陆逸华; 张鹏; 张田田; 张俊峰
200011 上海交通大学医学院附属第九人民医院心血管内科
Author(s):
WEI Meng;  JIANG Zheyi;  LU Yihua;  ZHANG Peng;  ZHANG Tiantian;  ZHANG Junfeng
Department of Cardiology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China
关键词:
端粒酶抑制剂; 血小板活化; 核因子-κB通路
Keywords:
Telomerase inhibitor; Platelet activation; NF-κB pathway
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2025.01.013
文献标识码:
-
摘要:
目的：探讨端粒酶抑制剂BIBR1532对血小板活化功能的影响。方法：取野生型8～12周龄雄性C57BL/6小鼠20只，制备洗涤血小板，并分成空白对照组、阳性对照组和BIBR1532处理组（终浓度5μmol/L和10μmol/L）。经孵育后，测定血小板聚集、铺展程度和血块收缩速率及血小板活化标志物P-选择素（CD62P）和血小板膜糖蛋白Ⅱb/Ⅲa纤维蛋白原受体（PAC-1）。采用Westernblot法检测不同组静息和活化状态下血小板中关键信号通路蛋白质的磷酸化水平。结果：与空白对照组相比，BIBR1532
Abstract:
Objective: To investigate the impact of telomerase inhibitor BIBR1532 on platelet activation.? Methods: Washed platelets were prepared from 20 male C57BL/6 wild-type mice (8-12 weeks), and divided into experimental and vehicle groups. The experimental gro

参考文献/References

[1] GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159):1736-1788.
[2] Jackson SP. Arterial thrombosis—insidious, unpredictable and deadly[J]. Nat Med, 2011, 17(11):1423-1436.
[3] Davì G, Patrono C. Platelet activation and atherothrombosis[J]. N Engl J Med, 2007, 357(24):2482-2494.
[4] Furie B, Furie BC. Mechanisms of thrombus formation[J]. N Engl J Med, 2008, 359(9):938-949.
[5] Bryan C, Rice C, Hoffman H, et al. Structural basis of telomerase inhibition by the highly specific BIBR1532[J]. Structure, 2015, 23(10):1934-1942.
[6] Altamura G, Degli Uberti B, Galiero G, et al. The small molecule BIBR1532 exerts potential anti-cancer activities in preclinical models of feline oral squamous cell carcinoma through inhibition of telomerase activity and down-regulation of TERT[J]. Front Vet Sci, 2021, 7:620776.
[7] Chen X, Tang WJ, Shi JB, et al. Therapeutic strategies for targeting telomerase in cancer[J]. Med Res Rev, 2020, 40(2):532-585.
[8] Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis[J]. N Engl J Med, 2015, 373(10):908-919.
[9] 齐茗,王晨霞. 血小板活化标志物CD62P、PAC-1与心血管病关系研究的进展[J]. 心血管康复医学杂志, 2014, 23(1):98-100.
[10] Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer[J]. Blood, 2015, 126(5):582-588.
[11] Hayden MS, Ghosh S. Shared principles in NF-κB signaling[J]. Cell, 2008, 132(3):344-362.
[12] Hayden MS, Ghosh S. NF-κB in immunobiology[J]. Cell Res, 2011, 21(2):223-244.
[13] Cheng WJ, Cui C, Liu G, et al. NF-κB, apotential therapeutic target in cardiovascular diseases[J]. Cardiovasc Drugs Ther, 2023, 37(3):571-584.
[14] Kojok K, El-Kadiry AE, Merhi Y. Role of NF-κB in platelet function[J]. Int J Mol Sci, 2019, 20(17):4185.
[15] Fuentes E, Rojas A, Palomo I. NF-κB signaling pathway as target for antiplatelet activity[J]. Blood Rev, 2016, 30(4):309-315.
[16] Nasrollahzadeh A, Bashash D, Kabuli M, et al. Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-κB signaling pathway[J]. Life Sci, 2020, 257:118060.
[17] Hussain T, Chai L, Wang Y, et al. Activation of PPAR-γ prevents TERT-mediated pulmonary vascular remodeling in MCT-induced pulmonary hypertension[J]. Heliyon, 2023, 9(3):e14173.
[18] Dratwa M, Wysoczańska B, ?acina P, et al. TERT-regulation and roles in cancer formation[J]. Front Immunol, 2020, 11:589929.
[19] Ferrer-Raventós P, Beyer K. Alternative platelet activation pathways and their role in neurodegenerative diseases[J]. Neurobiol Dis, 2021, 159:105512.
[20] Ding XF, Cheng JJ, Pang QS, et al. BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition[J]. Int J Radiat Oncol Biol Phys, 2019, 105(4):861-874.
[21] Xie XM, Li MX, Zhou MY, et al. Pharmacological preconditioning by TERT inhibitor BIBR1532 confers neuronal ischemic tolerance through TERT-mediated transcriptional reprogramming[J]. J Neurochem, 2021, 159(4):690-709.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82270340，81970289）
通信作者：张俊峰， E-mail：jfzhang_dr@163.com
更新日期/Last Update: 2025-02-10